Houston, TX 的 膀胱癌 臨床試驗
31 項針對 膀胱癌 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
招募中2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
招募中1/2 期
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
招募中1 期
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
招募中3 期
- University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
招募中1 期
- MD Anderson Cancer Center, Houston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
招募中2 期
- Houston Methodist, Houston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
招募中2 期
- Houston Metro Urology, Houston
- Houston Methodist Hospital, Houston
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
招募中3 期
- Houston Metro Urology, Houston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- MD Anderson Cancer Center, Houston
Measuring Surgical Recovery After Radical Cystectomy
招募中觀察性研究
- University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
招募中3 期
- M D Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
招募中1/2 期
- Houston Metro Urology, Houston
- Houston Methodist Hospital - Department of Urology, Houston
- University of Texas - MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
招募中1 期
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
招募中2 期
- Houston Methodist Neal Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
招募中觀察性研究
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
招募中1 期
- Baylor St. Luke's Medical Center, Houston
Blue Light Cystoscopy With Cysview® Registry
招募中觀察性研究
- Michael E. DeBakey VA Medical Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Houston
其他城市的 膀胱癌 試驗
- New York City, NY35 項研究
- Nashville, TN31 項研究
- Dallas, TX27 項研究
- Boston, MA26 項研究
- Washington, DC26 項研究
- Los Angeles, CA24 項研究
- Baltimore, MD24 項研究
- St. Louis, MO22 項研究
- Philadelphia, PA21 項研究
- Seattle, WA21 項研究
- Edison, NJ21 項研究
- Chicago, IL21 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。